INCY
INCYTE CORP
NASDAQ · Healthcare · Biotechnology · US
$113.25
+0.16%Year over year
Reported trailing growth
- Revenue
- +26.9%
- EBITDA
- +52.6%
- EBIT
- +84.8%
- EPS
- +80.7%
- Free cash flow
- +103.1%
- Operating cash flow
- +97.4%
Forward estimates
Based on analyst estimates
- Revenue
- +3.5%
- EBITDA
- +27.5%
- EPS
- -3.6%
Three-year CAGR
- Revenue
- +14.8%
- EBITDA
- +43.2%
- EBIT
- +31.4%
- Net income
- +55.7%
- EPS
- +62.7%
- Free cash flow
- +14.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026